# An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

> **NCT02225574** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** MEK-162
- **DRUG:** Nilotinib
- **BEHAVIORAL:** Questionnaires

## Key facts

- **NCT ID:** NCT02225574
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03-11
- **Primary completion:** 2017-02-02
- **Final completion:** 2017-02-02
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Slow Accrual - Only 1 patient enrolled in Phase 1 - Study never went to Phase II
- **Last updated:** 2020-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02225574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02225574, "An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02225574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*